Previous Close | 31.31 |
Open | 31.53 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 31.53 - 31.95 |
52 Week Range | 31.13 - 40.48 |
Volume | |
Avg. Volume | 1,828,936 |
Market Cap | 205.514B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 16.04 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.39 (4.45%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY
The company is pitching the test as a way to improve the safety and availability of blood.
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite, which investors in weight loss drug stocks have noticed. These drugs, combined with exercise and other diet enhancements, have proven effective. However, with FDA approvals for only certain conditions (depending on the label) and Medicare coverage differing by insurance provider, there’s still som